Dr. Thompson is Assistant Professor of Clinical Medicine at the University of California, Davis, School of Medicine with a joint appointment in the Departments of Medical Microbiology and Immunology, and Internal Medicine, Division of Infectious Diseases. Dr. Thompson specializes in the care of patients with invasive fungal infections and has research interest in fungal diagnostics and host immunogenetics. His current research focuses on the host-pathogen interaction of humans and both Coccidioides spp. (the agent of “Valley Fever”), and Cryptococcus spp. Dr. Thompson has served on the IDSA Journal Club which is a committee comprised of 12 panelists who select key papers for review and compose a summary of important articles that is published in the internationally disseminated monthly IDSA News. Additionally, he is a member of the Coccidioidomycosis Study Group Planning Committee, and as Co-chair of the Mycoses Study Group - a committee responsible for the development of content and dissemination of materials to practitioners across the United States, planning of the mycology content at yearly meetings (IDSA and ICAAC), and the design of clinical trials.

Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA is the Frances King Black Endowed Professor and Deputy Head-Research in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center. He is also an adjunct professor at Baylor College of Medicine and University of Houston College of Pharmacy in Houston Texas. He received his medical degree Summa Cum Laude from the National and Kapodistrian University of Athens in Greece. Dr. Kontoyiannis also completed a post-doctoral clinical research fellowship at the Section of Infectious Diseases at The University of Texas MD Anderson Cancer Center in Houston, TX, followed by training in Internal Medicine at Baylor College of Medicine in Houston, TX, where he served as a Chief Medical Resident. He was subsequently trained as a clinical fellow in Infectious Diseases at Massachusetts General Hospital and obtained a Master in Clinical Sciences from Harvard Medical School in Boston. He spent 3 years at the Whitehead Institute for Biomedical Sciences/Massachusetts Institute of Technology as a fellow in the Harvard MIT Clinical Investigators Training Program. Dr. Kontoyiannis has authored more than 450 peer-reviewed manuscripts and been invited to give over 150 lectures in international conferences and prestigious institutions in US and abroad. He serves as an associate editor for Mycoses and J of Infection and sits in the editorial Boards of Antimicrobial Agents & Chemotherapy, JID. Transplantation Infectious Diseases and he is a reviewer for several other peer-reviewed journals in Infectious Diseases ,Oncology and Hematology. An international expert in clinical and experimental mycology, and the top three most highly cited investigators in the area of mycology with over 450 peer reviwed manuscripts and over 27000 citations. He is a fellow of the American College of Physicians and the Infectious Diseases Society of America. He is the recipient of many awards such as the 2004 American Society for Microbiology award for Outstanding Research in the Pathogenesis of Microbial Diseases (mentor), the America's Top Physicians in from Consumer’s Research Council of America and The University of Texas MD Anderson Cancer Center 2004 Faculty E. N Cobb Scholar Award, Faculty Achievement Award, M. D. Anderson Cancer Center, 2007, The Distinguished Clinical Faculty Mentoring Award of at MD Anderson Cancer Center, 2012, The Billy Cooper Memorial award from The Medical Mycology Society of Americas (2013), America’s Top doctors (2015), The Drouhet Medal from the European Confederation of Medical Mycology (2015). He is the president elect of Immunocompromised Host Society (2016-2018).

Dr. Thomas F. Patterson received his Bachelor of Arts degree from Baylor University, in Waco, Texas and his Medical Doctor from the University of Texas Medical School at Houston, Texas. He completed his internship and residency at Vanderbilt University Medical School, in Nashville, Tennessee and Yale-New Haven Hospital, and a fellowship in infectious diseases at Yale University School of Medicine, New Haven, Connecticut where he also served as an Assistant Professor of Medicine. Dr. Patterson currently is a Professor of Medicine and Chief, Division of Infectious Diseases at the University of Texas Health Science Center in San Antonio, Texas. He is also Director of the San Antonio Center for Medical Mycology. He has extensive experience in invasive fungal infections. His clinical and research interests focus on the diagnosis and treatment of fungal diseases particularly in immunocompromised hosts. He has been involved in developing new antifungal drugs and in clinical trials of new antifungal compounds. Dr. Patterson has published and lectured extensively on fungal infections. He has served as member of the American Board of Internal Medicine, Subspecialty Committee for Infectious Diseases, a Fellow of the American College of Physicians, Past-President of the Texas Infectious Disease Society, and current President, Immunocompromised Host Society.

Dr. Nathan P. Wiederhold is Associate Professor of Pathology and Medicine/Infectious Diseases at the University of Texas Health Science Center at San Antonio, and Adjoint Associate Professor of Pharmacy, at the University of Texas at Austin College of Pharmacy. Dr. Wiederhold received his Pharm.D. from the University of Texas at Austin in 2000, followed by pharmacy practice and infectious diseases clinical residencies at Barnes Jewish Hospital, St. Louis, Missouri. He then completed a two-year research fellowship in antifungal pharmacology/medical mycology at the University of Houston and UT MD Anderson Cancer in Houston, Texas. Dr. Wiederhold then joined the faculty of the University of Texas at Austin and the University of Texas Health Science Center at San Antonio in 2004. He then became the director of the Fungus Testing Laboratory in 2013. Dr. Wiederhold’s clinical and research areas include medical mycology, antifungal susceptibility and resistance, and antifungal therapeutic drug monitoring. He has over 100 peer-reviewed publications in this area, and his work has been supported by the National Institutes of Health, various professional organizations, and industry.